CryoLife, Inc. (NYSE:CRY) will be announcing its earnings results after the market closes on Tuesday, October 24th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. CryoLife has set its FY17 guidance at $40-0.43 EPS.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The company had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. During the same period last year, the company earned $0.13 EPS. CryoLife’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, analysts expect CryoLife to post $0.34 EPS for the current fiscal year and $0.41 EPS for the next fiscal year.

Shares of CryoLife, Inc. (NYSE:CRY) opened at 20.30 on Tuesday. The company has a market capitalization of $678.95 million, a P/E ratio of 61.52 and a beta of 0.92. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company has a 50-day moving average price of $22.03 and a 200 day moving average price of $19.26.

In other news, CEO James P. Mackin sold 125,000 shares of CryoLife stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James Benson sold 2,000 shares of CryoLife stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 171,050 shares of company stock worth $3,769,825. 6.00% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at

Several research firms recently commented on CRY. Lake Street Capital raised their target price on CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 target price on shares of CryoLife in a report on Monday, October 9th. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Finally, BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. CryoLife presently has a consensus rating of “Buy” and a consensus price target of $23.63.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.